All Oncology News

Tislelizumab has been approved in Europe across 3 indications in the first and second line for select patients with non–small cell lung cancer.

Health Canada has approved subcutaneous atezolizumab for use in patients with lung cancer, breast cancer, and hepatocellular carcinoma.

VCN-01 was safe and elicited signs of antitumor activity in patients with intraocular retinoblastoma that was refractory to chemotherapy or radiotherapy.

In the wake of the cyberattack and subsequent outage of Change Healthcare, Florida Cancer Specialists & Research Institute stands resolute in its commitment to patient care and safety.

Investigators examined 100 metastases and developed a Uveal Melanoma Immunogenomic Score to predict which patients will respond to immunotherapy.

The MyProstateScore 2.0 urine test led to greater diagnostic accuracy for high-grade prostate cancer compared with existing biomarker tests.

The FDA has approved nogapendekin alfa inbakicept-pmln plus BCG for BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors.

SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.

Paul V. Viscuse, MD, spotlights key data from the 2024 Genitourinary Cancers Symposium in bladder cancer and renal cell carcinoma.

Debu Tripathy, MD, highlights the potential role and significance of vepdegestrant in pretreated ER-positive/HER2-negative breast cancer.

Oliver Dorigo, MD, PhD, discusses the investigation of CRX100 in patients with recurrent, platinum-resistant ovarian cancer.

Targeted therapy, genomics, and treatment disparities were among the topics that were presented by researchers from UCSF at the 2024 AACR conference.

The FDA has granted breakthrough therapy designation to ziftomenib for the treatment of NPM1-mutant acute myeloid leukemia.

Cilta-cel has received approval from the European Commission for multiple myeloma that is relapsed or refractory to at least 1 prior line of therapy.

Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of cilta-cel in relapsed/refractory multiple myeloma.

Tivumecirnon plus pembrolizumab elicited responses in recurrent or metastatic head and neck squamous cell carcinoma after checkpoint inhibitor exposure.

Idalid Franco, MD, MPH, discusses the integration of immunotherapy, molecular biomarkers, and risk factors for recurrence into the endometrial cancer paradigm.

Premal Thaker, MD, MS, discusses how the RAMP-201 trial paved a way for the RAMP-301 trial of avutometinib/defactinib in low-grade serous ovarian cancer.

In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.

The current health care economy has driven many employers to self-funding models to offer affordable health care coverage to employees.

Health Canada has approved pembrolizumab plus chemotherapy for first-line, locally advanced, unresectable, or metastatic, HER2-negative gastric/GEJ cancer.

In a survey, over 200 oncologists agreed on how AI can be responsibly integrated into patient care and how to protect patients from hidden biases of AI.

The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.

R. Lor Randall, MD, FACS, discusses the changing field of orthopedic oncology and gives his takeaways from the American Academy of Orthopedic Surgeons Meeting.

A unique approach combining genomic and sensitivity testing with machine learning was feasible for guiding treatment selection in pediatric cancers.

The FDA has approved alectinib as adjuvant treatment in select patients with ALK-positive non–small cell lung cancer.

Matthew S. Johnson, MD, discusses a pilot study of Y-90 radioembolization plus pembrolizumab in patients with poor-prognosis hepatocellular carcinoma.

Experts discuss the FDA's call for a boxed warning for secondary T-cell malignancies on all approved CAR T-cell agents in late January 2024.

Eric S. Christenson, MD, discusses the potential benefit of copanlisib plus nivolumab in PIK3CA-mutant microsatellite stable colorectal cancer.